XRTX XORTX Therapeutics Inc.
$1.06▲ +15.20%
Healthcare
Other
Volume 118.5K
Avg Volume (10D) 255.8K
Key Metrics & Fundamentals
Market Cap
$1.93M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.83 - 3.65
% vs 50 MA
-41.37%
% vs 200 MA
-50.99%
RSI-14
35.5
MACD Histogram
-0.0400
Beta (1Y vs SPY)
0.95
Free Cash Flow
-$3.41M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.67M
COGS
–
Operating Exp
$1.69M
Operating Income
-$1.69M
EBIT
-$1.69M
Pretax Income
-$1.69M
Net Income
-$1.69M
EPS (Diluted)
-1.05
Price & Volume History
Loading chart…
Recent News
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
GlobeNewswire · Oct 8, 2026 4:00 PM ET
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
GlobeNewswire · Sep 18, 2026 8:05 AM ET
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
GlobeNewswire · Sep 10, 2026 4:05 PM ET
XORTX Re-Engages Investor Relations Program
GlobeNewswire · Sep 8, 2026 6:15 PM ET
XORTX Announces Termination and Postponement of Investor Relations Program
GlobeNewswire · Aug 28, 2026 7:00 AM ET
XORTX Announces Director Resignation
GlobeNewswire · Jul 31, 2026 5:00 PM ET
XORTX Appoints New Director
GlobeNewswire · Jul 29, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See XRTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.